SCHEMBL4024645

SCHEMBL4024645

CC(C)(C)[Si](C)(C)Oc1ccc(C=NO)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.49
MEN1 O00255 1/20 0.49
GFER P55789 3/20 0.45
MAPK1 P28482 2/20 0.45
MAPT P10636 3/20 0.45
ALDH1A1 P00352 2/20 0.45
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
CASP3 P42574 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
GAA P10253 2/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
PREP P48147 2/20 0.41
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4024641 1.00 KMT2A (0.49) KMT2AMEN1GFERMAPK1MAPT
SCHEMBL7189378 0.81 CA12 (0.46) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4892908 0.81 PREP (0.37) KMT2AMEN1GFERMAPK1MAPT
SCHEMBL4892901 0.81 PREP (0.37) KMT2AMEN1GFERMAPK1MAPT
SCHEMBL6763899 0.80 PREP (0.53) ALDH1A1PREPCA12CA1CA9
SCHEMBL4271978 0.79 PREP (0.41) MAPTALDH1A1CYP1A2PREPCA12
SCHEMBL896879 0.78 ALDH1A1 (0.50) KMT2AMEN1MAPTALDH1A1SMN1; SMN2
SCHEMBL37002 0.78 PREP (0.43) ALDH1A1PREPCA12CA1CA9
SCHEMBL7822309 0.78 S100B (0.59) KMT2AMEN1MAPK1MAPTALDH1A1
SCHEMBL7822307 0.78 S100B (0.59) KMT2AMEN1MAPK1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296711-B2 Substituted isoxazole amide compounds as inhibitors of stearoyl-CoA desaturase 1 (SCD1) HOFFMAN-LA ROCHE INC. (US) 2016-03-29 US disclosed
US-20150307463-A1 SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1) HOFFMANN-LA ROCHE INC. 2015-10-29 US disclosed
EP-2925751-A1 SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1) F. Hoffmann-La Roche AG (CH) 2015-10-07 EP disclosed
WO-2014086704-A1 SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1) F. HOFFMANN-LA ROCHE AG (CH) 2014-06-12 WO disclosed
US-20130041000-A1 NOVEL AZOLE COMPOUND AJINOMOTO CO., INC. (JP) 2013-02-14 US disclosed
US-20090170911-A1 NOVEL AZOLE COMPOUND AJINOMOTO CO. INC (JP) 2009-07-02 US disclosed
US-7517996-B2 Azole compound AJINOMOTO CO., INC. (JP) 2009-04-14 US disclosed
US-20060194850-A1 Novel azole compound AJINOMOTO CO. INC (JP) 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170911-A1 NOVEL AZOLE COMPOUND LPAR1, LPAR2, LPAR3 KMT2A 1367/4885MEN1 1453/4885GFER 824/4885
US-20150307463-A1 SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1) SCD, SCD5, CPT1A KMT2A 2886/4885MEN1 4469/4885GFER 1307/4885
US-20130041000-A1 NOVEL AZOLE COMPOUND LPAR1, LPAR2, LPAR3 KMT2A 1367/4885MEN1 1453/4885GFER 824/4885
US-20060194850-A1 Novel azole compound LPAR1, LPAR2, LPAR3 KMT2A 1367/4885MEN1 1453/4885GFER 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.